Kaplan-Meier curves. PFS (A); duration of response (B); PFS by high or low tumor burden according to GELF criteria (C); PFS by PD <1 year or PD >/=1 year from prior treatment (D); OS in patients with R/R FL receiving pembrolizumab+rituximab (E). E, number of events; N, sample size.